International Clinical Trial: A single-center, randomized, double-blind, placebo-controlled phase IIa clinical trial evaluating the safety and pharmacokinetic profile of standard treatment in combination with butaselen tablets in patients with fibrosing interstitial lung disease

Geneva, April 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600122134) titled 'A single-center, randomized, double-blind, placebo-controlled phase IIa clinical trial evaluating the safety and pharmacokinetic profile of standard treatment in combination with butaselen tablets in patients with fibrosing interstitial lung disease' on April 9.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: China-Japan Friendship Hospital

Condition: fibrosing interstitial lung disease

Intervention: Treatment group:Treatment period: standard treatment (decided by clinical investigator) + butaselen tablet (450mg) Day1-Day6(D1-D6), orally, b.i.d Day7(D7), qd Extension period: stand...